drugset
drugset / Trial / NCT00126555

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

NCT00126555 ↗

Phase 2 Completed 23 enrolled National Cancer Institute (NCI)
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if giving Iressa (Gefitinib or ZD1839) with surgery and/or radiation will help to control squamous cell carcinoma of the skin. The safety of this treatment will also be studied

Timeline

Start
2005-03
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule 250 mg Oral
Subject Gefitinib Small molecule 500 mg Oral

Indications

skin squamous cell carcinoma